The latest price target for Humacyte (NASDAQ:HUMA) was reported by Cantor Fitzgerald on September 20, 2024. The analyst firm set a price target for $13.00 expecting HUMA to rise to within 12 months (a possible 151.94% upside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for Humacyte (NASDAQ:HUMA) was provided by Cantor Fitzgerald, and Humacyte reiterated their overweight rating.

There is no last upgrade for Humacyte

There is no last downgrade for Humacyte.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on September 20, 2024 so you should expect the next rating to be made available sometime around September 20, 2025.

While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a reiterated with a price target of $13.00 to $13.00. The current price Humacyte (HUMA) is trading at is $5.16, which is out of the analyst’s predicted range.